Microglia-specific knock-down of Bmal1 improves memory and protects mice from high fat diet-induced obesity

Xiao-Lan Wang1,2,3, Sander Kooijman4, Yuanqing Gao2,3

  • 1Université de Strasbourg, Laboratoire de Neuroscience Cognitives et Adaptatives (LNCA), Strasbourg, France.

Insights

Disrupting the microglial clock gene Bmal1 enhances brain cell cleanup and protects against obesity and memory loss. This suggests targeting microglial Bmal1 could treat metabolic and cognitive disorders.

Area of Science:

  • Neuroscience
  • Chronobiology
  • Metabolic research

Background:

  • Microglia, the brain's immune cells, exhibit circadian rhythms influencing neural function.
  • The precise role of this intrinsic clock in microglial function under stimulated conditions, like metabolic stress or memory formation, remains unclear.

Purpose of the Study:

  • To investigate the impact of microglial-specific knockdown of the core clock gene Bmal1 on microglial phagocytosis and its functional consequences.
  • To determine if Bmal1 regulates microglial responses during metabolic challenges and cognitive processes.

Main Methods:

  • Microglia-specific knockdown of the Bmal1 gene in mice.
  • High-fat diet (HFD) induction to simulate metabolic stress.
  • Assessment of microglial phagocytosis, pro-opiomelanocortin (POMC) retention in the hypothalamus, and hippocampal spine maturation.
  • Evaluation of HFD-induced obesity and performance in memory tests.

Main Results:

  • Microglia-specific Bmal1 knockdown increased microglial phagocytosis under HFD and during cognitive tasks.
  • Enhanced phagocytosis correlated with retained POMC-immunoreactivity and hippocampal spine maturation.
  • Loss of Bmal1 protected mice from HFD-induced obesity and improved memory test performance.

Conclusions:

  • The intrinsic clock machinery in microglia, regulated by Bmal1, normally restrains phagocytosis.
  • Loss of Bmal1 enhances microglial phagocytosis, providing neuroprotection during metabolic stress and learning.
  • Microglial Bmal1 is a potential therapeutic target for metabolic and cognitive disorders, including psychiatric diseases.

Related Concept Videos